Last reviewed · How we verify
Fumaric acids
Fumaric acid is thought to modulate the immune system by inhibiting the production of pro-inflammatory cytokines.
Fumaric acid is thought to modulate the immune system by inhibiting the production of pro-inflammatory cytokines. Used for Psoriasis.
At a glance
| Generic name | Fumaric acids |
|---|---|
| Sponsor | Swiss Dermatology Network for Targeted Therapies |
| Drug class | Immunomodulator |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Fumaric acid has been shown to have immunomodulatory effects, reducing the production of pro-inflammatory cytokines such as TNF-alpha and IL-1beta, which are involved in the pathogenesis of psoriasis.
Approved indications
- Psoriasis
Common side effects
- Gastrointestinal disturbances
- Headache
- Fatigue
Key clinical trials
- A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis (PHASE4)
- Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID (PHASE2)
- PsoBest - The German Psoriasis Registry
- Swiss Dermatology Network of Targeted Therapies (SDNTT)
- A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function (NA)
- APremilast After FumaRic Acid Ester Treatment
- Modulation of the Gut-brain Axis by Cranberries: Impact on University Students' Mental Wellbeing (NA)
- Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fumaric acids CI brief — competitive landscape report
- Fumaric acids updates RSS · CI watch RSS
- Swiss Dermatology Network for Targeted Therapies portfolio CI